rabeprazole
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Asthma
Conditions
Asthma, Gastroesophageal Reflux Disease
Trial Timeline
Sep 1, 2002 โ Mar 1, 2005
NCT ID
NCT00214552About rabeprazole
rabeprazole is a phase 3 stage product being developed by Eisai for Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT00214552. Target conditions include Asthma, Gastroesophageal Reflux Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00222170 | Phase 2 | Completed |
| NCT00214552 | Phase 3 | Completed |
Competing Products
20 competing products in Asthma